About
Dr. Yi-Yen Chen has over 10 years of healthcare-related experience. Prior to joining PCI…
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
-
-
Volunteer Experience
-
Consultant
Taiwan Tongzhi Hotline Association
Helpline telephone counselor to provide crisis aid and suicide prevention for LGBTQ+ youth and their families
-
San Francisco Programming Board
StartOut
- 1 year 2 months
Economic Empowerment
Silicon Valley + the Castro = StartOut's largest and most active chapter. Founded in 2009, the San Francisco chapter includes 3,300 people and is home to the first-ever LGBTQ Accelerator - the StartOut Growth Lab.
Publications
Organizations
-
Dutch Society for Immunology
-
Other similar profiles
Explore more posts
-
Filiz Hyden
𝑨𝑰 𝒎𝒆𝒆𝒕𝒔 𝒃𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒔: 𝑻𝒂𝒌𝒆𝒅𝒂 𝒂𝒏𝒅 𝑵𝒂𝒃𝒍𝒂 𝑩𝒊𝒐 𝒆𝒙𝒑𝒂𝒏𝒅 𝒕𝒉𝒆𝒊𝒓 𝒑𝒂𝒓𝒕𝒏𝒆𝒓𝒔𝒉𝒊𝒑 𝒊𝒏 𝒏𝒆𝒙𝒕-𝒈𝒆𝒏𝒆𝒓𝒂𝒕𝒊𝒐𝒏 𝒅𝒓𝒖𝒈 𝒅𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚 🤝 The partnership will harness Nabla Bio’s proprietary Joint Atomic Model (JAM) platform for the de novo design of antibodies within Takeda’s early-stage development programs. Nabla Bio will receive “double-digit millions” in upfront and research payments with potential success-based milestones exceeding $1 billion. For Takeda, this move underscores their strategic pivot toward AI-enabled drug development, following its recent decision to wind down internal cell therapy research. 🔹️ It reflects a wider industry shift as companies like AstraZeneca and Eli Lilly use generative AI to reshape early drug discovery. 🤖+🔬 AI and biologics together are transforming the pace and the possibilities of therapeutic innovation. #AI #Biotech #DrugDiscovery #Takeda #NablaBio #Biologics #Partnerships
2 Comments -
Marianna Bonechi
🚀 Exciting milestone for Dnipro VC portfolio company, Revalia Bio! Revalia has been awarded up to USD 27M from ARPA-H contract award to advance their Human Data Trial platform, a human-first approach that is transforming drug development. By leveraging donated human organs, organ-on-chip systems, and multimodal datasets, Revalia is building AI-driven models that predict drug safety and efficacy without relying on animal testing. This award validates Revalia’s mission: turning human data into actionable insights that accelerate safer therapies and reduce costly late-stage failures. It’s a true paradigm shift in how medicine is developed. At the heart of its mission, this program enables Revalia Bio to honor the legacy of every donor by transforming the loss of one life into knowledge that shapes the future of medicine. https://lnkd.in/geAfe3Eq 👏 Congratulations to Greg Tietjen, Peter Buniak, Milad Alucozai and the eintre Revalia team!
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content